Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Robert Tighe

Systemic Immunotherapy of Superficial Mouse Bladder Cancer With Avelumab (MSB0010718C), an Anti-Pd-L1 Immune Checkpoint Inhibitor

Journal for ImmunoTherapy of Cancer

English

NHS-IL2 Combined With Radiotherapy: Preclinical Rationale and Phase Ib Trial Results in Metastatic Non-Small Cell Lung Cancer Following First-Line Chemotherapy

Journal of Translational Medicine

English

Related publications

Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-Pd-L1 Immune Checkpoint Inhibitor

Frontiers in Oncology

Cancer Research

Oncology

2020

English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer

Oncology

2020

English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology

English

Avelumab, an Anti-Pd-L1 Antibody, in Patients With Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor Study

Breast Cancer Research and Treatment

Cancer Research

Oncology

2017

English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research

Cancer Research

Immunology

2015

English

Intravesical Immunotherapy of Superficial Bladder Cancer With Chitosan/Interleukin-12

Cancer Research

Oncology

2009

English

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma

Expert Review of Clinical Pharmacology

English

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

International Journal of Endocrinology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Robert Tighe

Systemic Immunotherapy of Superficial Mouse Bladder Cancer With Avelumab (MSB0010718C), an Anti-Pd-L1 Immune Checkpoint Inhibitor

NHS-IL2 Combined With Radiotherapy: Preclinical Rationale and Phase Ib Trial Results in Metastatic Non-Small Cell Lung Cancer Following First-Line Chemotherapy

Related publications

Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-Pd-L1 Immune Checkpoint Inhibitor

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Avelumab, an Anti-Pd-L1 Antibody, in Patients With Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor Study

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Intravesical Immunotherapy of Superficial Bladder Cancer With Chitosan/Interleukin-12

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model